MRI-Guided radiation aims to hit tumors harder, spare healthy tissue

NCT ID NCT04115254

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This master trial is testing a new radiation technique called SMART, which uses MRI to guide and adapt radiation beams in real time. The goal is to deliver high doses precisely to tumors while protecting nearby organs. The study enrolls adults with various cancers (pancreas, lung, kidney, prostate, liver, and others) and has two phases: Phase I checks if the treatment is safe and feasible, and Phase II looks at how well it controls tumors and improves patient quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MR-guided radiation therapy (SMART)
What this could lead to: If successful, this could show that SMART is a safe and effective way to deliver high-precision radiation to many types of tumors, potentially improving tumor control and reducing side effects.
What could go wrong: This is an early-phase trial (Phase I/II) with no control group, so results may not prove superiority over standard radiation. Side effects from high-dose radiation are possible, and success in one tumor type may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer kidney cancer lung cancer lung neoplasm malignant pancreatic neoplasm mesothelioma metastatic carcinoma in the bone pancreatic neoplasm prostate cancer renal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL METASTASES BORDERLINE RESECTABLE PANCREATIC CARCINOMA BRAIN METASTASES LIVER METASTASES LUNG CANCER MESOTHELIOMA METACHRONOUS NODAL METASTASES OLIGOPROGRESSIVE NODAL METASTASES PANCREAS CANCER PROSTATE CANCER RENAL CANCER SPINE METASTASES SYNCHRONOUS NODAL METASTASES

Contacts and locations

Locations

Brigham & Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.